SAN DIEGO, May 15, 2006 /PRNewswire-FirstCall via COMTEX News Network/ —ACADIA Pharmaceuticals Inc.(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments for centralnervous system disorders, today announced that it was selected for addition tothe NASDAQ Biotechnology Index (NBI), effective as of the market's opening onMay 22, 2006.
"We are pleased to be included in the NASDAQ Biotechnology Index andbelieve that our selection to this index is further recognition of ourconsistent progress and achievements," said Uli Hacksell, Ph.D., ChiefExecutive Officer of ACADIA. "We look forward to continuing to execute on ourstrategy of building a broad pipeline of innovative therapies to treat centralnervous system disorders and other areas of unmet medical need."
Launched in 1993, the NASDAQ Biotechnology Index includes companies thatare listed on the NASDAQ national market and meet minimum requirements,including market value, average daily share volume, and seasoning as a publiccompany, among other criteria. The index is ranked on a semi-annual basis inMay and November and serves as the basis for the iShares NASDAQ BiotechnologyIndex Fund (Amex: IBB). For more information about the NASDAQ BiotechnologyIndex, including eligibility criteria, visit www.nasdaq.com.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments for centralnervous system disorders. ACADIA currently has five Phase II-stage clinicalprograms as well as a portfolio of preclinical and discovery assets directedat large unmet medical needs, including schizophrenia, Parkinson's disease,sleep maintenance insomnia, and neuropathic pain. All of the drug candidatesin ACADIA's product pipeline emanate from discoveries made using itsproprietary drug discovery platform. ACADIA's corporate headquarters islocated in San Diego, California and it maintains research and developmentoperations in both San Diego and Malmo, Sweden.
Forward-Looking Statements
Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but are notlimited to statements related to the progress and potential of ACADIA'sprograms and business. These statements are only predictions based on currentinformation and expectations and involve a number of risks and uncertainties.Actual events or results may differ materially from those projected in any ofsuch statements due to various factors, including the risks and uncertaintiesinherent in drug discovery, development and commercialization, collaborationswith others, and litigation. For a discussion of these and other factors,please refer to ACADIA's annual report on Form 10-K for the year endedDecember 31, 2005 as well as other subsequent filings with the Securities andExchange Commission. You are cautioned not to place undue reliance on theseforward-looking statements, which speak only as of the date hereof. Thiscaution is made under the safe harbor provisions of the Private SecuritiesLitigation Reform Act of 1995. All forward-looking statements are qualifiedin their entirety by this cautionary statement and ACADIA undertakes noobligation to revise or update this press release to reflect events orcircumstances after the date hereof.
Contacts:
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and Chief Financial Officer
(858) 558-2871